Inventiva (NASDAQ:IVA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Inventiva (NASDAQ:IVA) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

Several other analysts also recently weighed in on IVA. Stifel Nicolaus dropped their target price on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, November 22nd. UBS Group began coverage on Inventiva in a research report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 price target for the company.

Inventiva Price Performance

IVA stock opened at $2.48 on Thursday. The business has a fifty day moving average of $2.36 and a two-hundred day moving average of $2.35. Inventiva has a 52-week low of $1.53 and a 52-week high of $4.50.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.